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ABSTRACT
Introduction: Oral vaccines delivered as tablets
offer a number of advantages over traditional
parenteral-based vaccines including the ease of
delivery, lack of needles, no need for trained
medical personnel, and the ability to formulate
into temperature-stable tablets. We have been
evaluating an oral vaccine platform based on
recombinant adenoviral vectors for the purpose
of creating a prophylactic vaccine to prevent
influenza, and have demonstrated vaccine
efficacy in animal models and substantial
immunogenicity in humans. These studies
have evaluated monovalent vaccines to date.
To protect against the major circulating A and B
influenza strains, a multivalent influenza
vaccine will be required.
Methods: In this study, the immunogenicity of
orally delivered monovalent, bivalent, trivalent,
and quadrivalent vaccines was tested in ferrets
and mice. The various vaccine combinations
were tested by blending monovalent
recombinant adenovirus vaccines, each
expressing hemagglutinin from a single strain.
Human tablet delivery was modeled in animals
by oral gavage in mice and by endoscopic
delivery in ferrets.
Results: We demonstrated minimal
interference between the various vaccine
vectors when used in combination and that
the oral quadrivalent vaccine compared
favorably to an approved trivalent inactivated
vaccine.
Conclusion: The quadrivalent vaccine
presented here produced immune responses
that we predict should be capable of providing
protection against multiple influenza strains,
and the platform should have applications to
other multivalent vaccines.
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INTRODUCTION
Influenza virus infections are a major cause of
acute seasonal respiratory illness, which causes
significantmorbidity andmortality. Vaccination
is an effective way of reducing the numbers of
infected individuals provided there is a good
match between the vaccine and the circulating
strains. Every February in the Northern
Hemisphere the circulating strains for the next
season are chosen by the World Health
Organization, which allows approximately
6 months for sufficient vaccine to be generated.
Annual influenza vaccines need to provide
protection against the predominant influenza
strains that are present in each season’s
outbreaks. Since 1977, A/H1N1, A/H3N2, and B
viruses are the major virus types that are in
circulation. Choosing only one B strain was not
always accurate as indicated during the period of
2001–2010 in the USA when the trivalent
influenza strain only partially matched the
circulating B strain 50% of the time [1].
Licensed vaccines today use three (two A and
one B) or four (two A and two B) strains that are
predicted tobe circulating in thepopulation. The
additional B strain in the quadrivalent vaccine is
due to the fact that there are two B lineages (B/
Yamagata and B/Victoria) currently in
co-circulation and there is limited cross
protection between strains from each lineage
[2]. In a study using UK data, it was estimated
that the inclusion of an additional B strain to
generate a quadrivalent vaccine could be
expected to reduce the number of influenza
cases by 17,088 and deaths by 168 in the first
year of use [3]. Although adding four strains may
reduce the possibility of B strain mismatch,
strain mismatch can still occur as was the case
for the 2014/15 Northern Hemisphere influenza
season, where the predominant H3N2 strain
drifted [34], with the result that the vaccine was
only partially protective (vaccine effectiveness of
only 23%) [35]. While four strains may be better
than one, strain selection is by nomeans perfect.
An additional issue that arises withmultivalent
vaccines is the possibility of immunological
interference effects between the individual
vaccine components. Interference can result in a
diminished or an enhanced response to one
component in the presence of another. This has
been documented for live attenuated influenza
vaccines [4], andwhere it occurs, dosingmay have
to be modified to counteract this interference [5].
As new quadrivalent vaccines are developed,
interference effects need to be studied for each
new vaccine.
We have been developing an oral-based
adenovirus platform for vaccine delivery. The
vaccine platform consists of a
replication-incompetent adenovirus vector
bearing two expression cassettes that express a
vaccine antigen and a double-stranded RNA
(dsRNA) adjuvant [6]. The vaccine antigen that
we have chosen for the influenza vaccine is
influenza hemagglutinin (HA), an envelope
glycoprotein involved in receptor binding and
viral fusion. Antibodies that block the ability of
HA to bind to target cells, as measured by the HA
inhibition (HAI) titer, have been found to
correlate with protection [7]. This oral vaccine
approach has a number of advantages over
traditional influenza vaccines. These include
ease of manufacturing, using standard
recombinant techniques and established viral
purification methods; ease of delivery without
needles or other devices that need qualified
medical support; long-term stability at room
temperature negating the need for cold storage.
This oral platform also generates minimal
anti-vector immunity thus permitting
revaccination and reuse [6]. We have generated
HA-based recombinant adenovirus (rAd) vaccine
vectors to individual influenza strains and
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demonstrated either protection in small animals
[6] or immunogenicity in humans [8, 9]. Results
from these studies demonstrate the ability of the
approach to generate neutralizing antibody
responses to influenza, with additional
advantages such as antibody durability and T
cell responses shown in the studies as well. Given
the commercial need for a seasonal vaccine that
covers more than one strain, we have explored
the utility of our platform to vaccinate against
multiple influenza strains simultaneously and
have evaluated whether significant interference
exists between the vaccine antigens. Here, we
model oral tablet delivery by measuring the
ability of ferrets to mount immune responses to
multiple strains following intestinal delivery to a
single site and establish a potential strategy for
eventual vaccine commercialization.
METHODS
Cell Lines, Trivalent Vaccine
HEK293 cells were propagated in Dulbecco’s
Modified Eagles Medium (DMEM) plus
GlutaMaxTM (Invitrogen, Carlsbad, CA, USA)
supplemented with 5% bovine serum (BS) and
antibiotics (10 units/mL penicillin and 10 lg/mL
streptomycin). Trivalent inactivated influenza
vaccine (TIV), Fluzone (Sanofi Pasteur, Inc.), was
composed of the strains: A/California/07/09;
A/Victoria/201/09 (A/Perth/16/09-like virus);
B/Brisbane/60/08, and used as a comparative
vaccine in the ferretquadrivalent studyevaluation.
Adenovirus Propagation
and Characterization
E1, E3 deleted rAd subtype-5 vectors were
produced using the AdEasyTM (Qbiogene,
Quebec, Canada) kit. The original non-codon
optimized sequences for the different HA genes
used in this study were obtained from GenBank
(NCBI, Bethesda, MD, USA). The following
Genbank accession numbers were used for the
HA constructs; FJ966082 for A/California/04/2009
(H1N1), GQ293081 for A/Perth/16/09 (H3N2),
CY11515.1 for B/Brisbane/60/2008 (B/Victoria)
and KC306166.1 for B/Wisconsin/01/2010. All
HA genes were human codon optimized and
synthesized by Blue Heron Biotechnology
(Bothel, WA, USA). The HA gene was
synthesized with flanking Kpn I sites, which
facilitated cloning into a
pShuttle-cytomegalovirus (CMV) vector
(Qbiogene) that also contained a human
ß-globin intron and the bovine growth
hormone polyadenylation(A) signal. This
construct also expressed a molecular adjuvant as
a short dsRNA hairpin under control of a second
CMV promoter and which utilized a minimal
synthetic polyadenylation(A) signal. The
adjuvant sequence was made by annealing
overlapping oligonucleotide primers and has
been described previously [6]. The shuttle
vectors were propagated in NeB10b cells (New
England Biolabs, Beverly, MA, USA), and screened
by restriction digests and HA-specific polymerase
chain reaction primers. Selected pShuttle clones
were used to generate adenovirus stocks by
recombination in BJ5183-AD1 bacteria
(Stratagene, La Jolla, CA, USA) and transfection
into HEK293 cells as previously described [6]. The
HA vaccine vectors were purified by CsCl
centrifugation and dialyzed into 20 mM Tris pH
8.0, 25 mM NaCl, 2.5% glycerol. The viral titer
(IU/mL) was determined by immunostaining
using a rabbit anti-adenovirus polyclonal
(Abcam, Cambridge, MA, USA) as the primary
antibody, an anti-rabbit HRP secondary (Bethyl
Laboratories, Montgomery, TX, USA) antibody
and the color substrate 3,30-diaminobenzidine
(DAB) for signal detection.
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Animal Experiments
Animal research was approved by the
Institutional Animal Care and Use Committees
(IACUC) at Vaxart (South San Francisco, CA,
USA) and Southern Research Institute (SRI)
(Birmingham, AL, USA). Six- to seven-week-old
BALB/c mice were acquired from Simonsen
Laboratories (Gilroy, CA, USA) and vaccinated
perorally (p.o.) similar to that described by
other investigators [10, 11]. Briefly, 0.2 mL of
7.5% sodium bicarbonate was given by 24G
feeding tube (Fine Science Tools, Foster City,
CA, USA) followed less than a minute later with
rAd in 0.2 mL of phosphate-buffered saline
(PBS). Adenovirus is pH sensitive, so stomach
neutralization protects against acid
degradation. Intra-nasal (i.n.) vaccinations
were performed similar to that described by
Moore et al. [12]. For oral dosage, 1.0 9 107 IU
per mouse was administered at day 0 and
week 4, and for i.n. dosing, 2 9 106 IU/mouse
was administered at day 0, unless specifically
stated. Plasma samples were acquired by
cheek-pouch lancet (Medipoint, Mineola, NY,
USA) at several time-points post-vaccination.
For i.n. vaccination and for plasma harvesting,
mice were anesthetized by isoflurane inhalation
using a certified vaporizer (VetEquip,
Livermore, CA, USA). Mouse experiments were
performed once, but the results are
representative of several similar experiments
where vectors have been blended.
Fitch ferrets (Triple F Farms, Sayre, PA, USA)
were used in the ferret studies. Ferrets were
prescreened to select those animals negative for
HAI titers to the given strains. For the bivalent B
vaccine evaluation, male ferrets (1052–1856 g)
of 20–24 weeks of age were used with N = 8 for
oral groups, N = 3 for intra-muscular (i.m.; with
the exception of N = 2 for the recombinant
adenoviral vector expressing HA from
B/Brisbane/60/08 where an animal died
prematurely at day 0 due to non-vaccine
issues). For the quadrivalent study,
16–17-week-old male and female ferrets
(677–1341 g) were used. Each group (Groups
1–7, n = 10; Group 8, n = 4) used equal numbers
of males and females. Each ferret experiment
was performed once with N = 8–10 to reduce
total animal use. Prior to p.o. vaccination,
ferrets were fasted between 1 and 4 h to allow
ample time for the gastric emptying. Viral
vectors were delivered to the small intestine
via a bronchoscope (used as an endoscope) as
previously described [6]. 1 9 109 IU of rAd
vectors were administered in 1 mL of PBS on
weeks 0 and 4. This dose represents
approximately 1:10 or 1:100 of a human
effective dose as described by Liebowitz et al.
[8] and Peters et al. [9]. For blended vectors, the
vaccines were first mixed and then 1 9 109 IU of
each vector component was administered. For
i.m. vaccinations, animals were dosed with
0.5 mL of either an rAd vector vaccine or TIV
(Fluzone; at one full human dose) injected into
the hind limb muscle.
HA Assays
Total anti-HA antibodies were measured
similarly as previously described [6]. Briefly,
microtiter plates (Nunc MaxiSorp, eBioscience,
Inc., San Diego, CA, USA) were coated in 19
carbonate buffer (0.1 M at pH 9.6) with 1.0 lg/
mL of a baculovirus-expressed influenza HA
protein (Protein Sciences Corporation, Meriden,
CT, USA). Plates were incubated overnight at
4 C in a humidified chamber, then blocked in
PBS ? 0.05% Tween 20 (PBST) ? 1% BS albumin
(BSA) solution for 1 h before washing. Plasma
samples were serially diluted in PBST. After a 2-h
incubation, plates were washed 59 with PBST.
Antibodies were then added, either as a mixture
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of anti-mouse immunoglobulin G1
(IgG1)-horseradish peroxidase (HRP) and
anti-mouse IgG2a-HRP (Bethyl Laboratories),
or alternatively, anti-mouse IgA-HRP (Bethyl
Laboratories) for mucosal samples. Each
secondary antibody was used at a 1:5000
dilution and incubated for 1 h. Plates were
washed at least five times. Antigen-specific
antibodies were detected with
3,30,5,50-tetramethylbenzidine (TMB) substrate
(Rockland, Gilbertsville, PA, USA) using a
microplate reader. H2SO4 was used as a stop
solution, and the plates were read at 450 nm on
an EMax enzyme-linked immunosorbent assay
(ELISA) plate reader (Molecular Devices,
Sunnyvale, CA, USA). Average mouse antibody
titers were reported as the reciprocal dilution
giving an absorbance value greater than the
average background plus two standard
deviations (SDs) unless otherwise stated. Ferret
antibody responses to HA were measured by a
similar ELISA protocol with the exception that
the secondary antibody was anti-Ferret IgG-HRP
(Bethyl Laboratories). Ferret sera antibody titers
were calculated by performing the ELISA on
both the day 0 and the test samples (days 28
and 56) on the same plate and a titer was
assigned as the reciprocal of the highest
dilution of the test sample where the value
was greater than the corresponding day 0
dilution by 0.04 or greater. The absorbance
value also had to be greater than the average
background (based on blocking buffer alone)
plus two SDs.
HAI titers were measured by Focus
Diagnostics (Cypress, CA, USA). The HAI
protocol was followed as described before [13]
using four HA units of the relevant viruses. In
brief, test sera were first treated with
receptor-destroying enzyme (RDE; Accurate
Chemical & Scientific, Westbury, NY, USA) at
a 1:3 ratio at 37 C for 18–20 h. The RDE was
then inactivated by incubation at 56 C for
30 min. Six volumes of saline was then added to
generate a final sera dilution of 1:10. Influenza
viruses were diluted to a working stock of 4 HA
units/25 lL. Washed turkey red blood cells
(Lampire Biological Products, Pipersville, PA,
USA) were prepared by washing 49 in PBS and
were resuspended in PBS at a final volume of
0.45%. A 1:2 dilution series of the 1:10
pre-diluted sera was prepared in columns 1–10
of a V-shaped polystyrene microtiter plate with
row 1 undiluted, rows 2–8 diluted in PBS, 25 lL
PBS well. Columns 11 and 12 contained
negative sera and no sera (PBS only)
respectively. 25 lL of an influenza stock (4 HA
units/25 lL) was added per well and incubated
for 1 h at room temperature. Fifty microliters of
the 0.45% RBC was added and incubated for
45 min. Agglutination was compared between
the test and PBS wells. HAI titers were assigned
as the reciprocal of the highest sera dilution
that completely prevented RBC agglutination.
The influenza B viruses were egg derived and
pretreated with ether (Virapur, San Diego, CA,
USA) prior to use in the HAI assay [14]. Both the
A/Perth/16/09 and A/California/07/09 strains
used were Madin–Darby canine kidney
(MDCK) derived.
Microneutralization (MN) assays for both the
blended B and quadrivalent ferret studies were
performed by SRI following a protocol described
by Rowe et al. [15]. In brief, sera were
inactivated at 56 C for 30 min and twofold
serial dilutions were made in 1% BSA/DMEM/
1X penicillin/streptomycin. The diluted sera
(50 lL) was mixed with an equal volume of
influenza viruses at 2 9 103 tissue culture
infectious dose 50 (TCID50)/mL and incubated
for 18 h at 37 C. Control wells of virus plus
dilution buffer or dilution buffer alone were
included on each plate. 100 lL of MDCK cells at
1.5 9 105/mL was added to each well. The plates
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were incubated for 18 h at 37 C and 5% CO2.
The monolayers were washed with PBS and
fixed in cold 80% acetone for 10 min. The
presence of viral protein was detected by an
anti-influenza A nucleoprotein (NP) ELISA using
an anti-NP antibody (Mab8251, Millipore,
Billerica, MA, USA). The detecting antibody
was an HRP-goat anti-mouse antibody
(Kirkegaard & Perry Laboratories, Gaithersburg,
MD, USA) at a 1:2000 dilution and the substrate
used for detection was o-phenylenediamine
dihydrochloride (0.5 mg/mL in 0.05 M
phosphate citrate buffer, pH 5.0/0.03% sodium
perborate). A titer was assigned as the reciprocal
of the highest dilution that neutralized greater
than 50% of the virus-only control. Values less
than 20 were assigned a value of 10. SRI used
egg-derived viruses obtained from the Centers
for Disease Control and Prevention. No MN
assay was available for the H3N2 strain as SRI
had previously established that ferret sera
generated too high a background with this
H3N2 strain.
Statistical Analysis
Significance between groups was determined by
Mann–Whitney analysis using Prism software or
by Fisher’s exact test (http://vassarstats.net/
tab2x2.html). P values \0.05 were considered
significant.
RESULTS
Monovalent and Blended Vectors Induce
HA-Specific Immunity in BALB/c Mice
Vaccinated via the Oral and Intra-Nasal
Routes
Monovalent adenovirus vector vaccines were
generated for HAs representing the major viral
strains circulating in the 2010/11 Northern
Hemisphere. Figure 1 shows a schematic
representation of the transgene and adjuvant
cassette. Expression of each of the HAs was
confirmed by Western blotting of infected cell
lysates with strain-specific antibodies (data not
shown).
To first examine the potential for blending,
adenoviruses were initially evaluated in BALB/c
mice, using blended monovalent vectors
compared to unblended monovalent vectors,
and using multiple routes of administration. A
trivalent configuration was tested first, with the
anti-HA IgG response measured by ELISA
(Fig. 2a). Oral gavage was used to deliver the
vaccine to mice p.o. The blend tested in this
experiment consists of a blend of 1 9 107 IU of
vectors expressing H1/California/04/09, H3/
Perth/16/09, and B/Brisbane/60/08 HA
antigens. These were compared to the vectors
tested alone and a naı¨ve group of animals and
demonstrated that the blended vectors behaved
comparably to the individual vectors. The
response to B/Brisbane/60/08 in the blend did
trend lower than for the animals treated with
the monovalent vaccine, but the difference was
not statistically significant (P = 0.361). There
was very little cross strain reactivity when sera
from the monovalent vectors was tested against
HA antigens from the other strains indicating
that antibodies to the specific HA in the
trivalent blended sera were generated by each
individual HA component.
The i.n. route was evaluated as an additional
mucosal route of delivery, and has the
advantage of less intra-group variability
compared to gavage delivery in mice. This
allowed the evaluation of additional
permutations on the blend data from p.o.
experiment described before. The two blending
permutations from the standard 1:1:1 blend that
were tested were a 1:10:1 blend where the
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B/Brisbane/60/08 HA vaccine was dosed ten
times higher than the H1 and H3 vaccines, and
a group in which the three vaccine components
(1:1:1) were dosed separately with 24 h between
doses (Fig. 2b). Again, there was no significant
difference between the blended and individual
vaccine groups in terms of immune responses to
each of the HAs (P = 0.2–0.99 by
Mann–Whitney analysis). If anything, the
trivalent trended higher for IgG antibody
responses to influenza B than the monovalent
(P = 0.2). The trivalent group with ten times
higher B vaccine dose did have a higher but not
significantly different immune response to the
(1:1:1) trivalent group, or to the monovalent B
group (P = 0.11 and 0.11 by Mann–Whitney
analysis, respectively). Vaccine staggering did
not appear to affect the immune response
compared to the blended group dosed with all
constituents at the same time.
Before beginning a quadrivalent study, an
additional experiment looking at cross
reactivity of B/Victoria and B/Yamagata HA
vaccines was performed in mice. Animals were
dosed with either Ad-B/Brisbane/60/08 (Ad-B/
Bris) (Victoria), Ad-B/Wisconsin/1/10 (Ad-B/
Wis) (Yamagata) or a blend of the two. All
vectors were dosed with each vector at
2 9 106 IU/animal. The Ad-B/Bris group
induced a geometric mean titer (GMT) of
5.82 9 103 ± 4.2 9 104 to B/Brisbane/60/08 and
1.12 9 103 ± 1.93 9 103 to B/Wisconsin/1/10
indicating substantial cross reactivity (Fig. 3).
As was the case for Ad-B/Bris, Ad-B/Wis induced
a GMT of 6.31 9 104 ± 3.97 9 104 to
B/Wisconsin/1/10 and 1.63 9 103 ± 4.46 9 103
Fig. 1 Schematic of vaccine expression cassettes. Codon
optimized HA genes from individual seasonal inﬂuenza
strains were cloned into an expression cassette driven by a
CMV promoter and upstream of the region coding for a
dsRNA sequence also under the control of a CMV promoter.
CMV Cytomegalovirus, BGH PA Bovine growth hormone
polyadenylation(A) signal, dsRNA Double-stranded RNA
adjuvant,HAHemagglutinin, intronBeta globin intron, SPA
Synthetic polyadenylation(A) signal
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to B/Brisbane/60/08 also indicating that Ad-B/
Wis induced substantial cross reactivity. When
combined, both vectors induced similar levels
of anti-HA IgG levels to both strains, with titers
of 3.65 9 104 ± 3.3 9 104 and 5.24 9 104 ±
4.519 104 for B/Wisconsin/1/10 and B/Brisbane/
60/08, respectively.
Endoscopic Delivery of Bivalent B Vaccine
Blend in Ferrets
Monovalent and bivalent Ad-B/Wis and Ad-B/
Bris vaccine compositions were tested by the
endoscopic route of delivery (p.o.) in ferrets as a
model of oral tablet delivery in humans. As a
Fig. 2 a Oral administration of Ad-HA vaccines in BALB/
c mice. 1 9 107 IU of each vector was either administered
as a blend, or individually. Vaccines were administered at
time 0 and week 4. Total anti-HA IgG ELISA was
performed on 8-week sera to evaluate anti-HA antibody
responses. Differences between monovalent and multivalent
vaccines were evaluated by Mann–Whitney analysis; A
strains P = 0.639, P = 0.361 for B strains, two tailed.
b Intra-nasal administration of Ad-HA vaccines in BALB/c
mice. For the blend of 1:1:1 and for all single-dosed vaccine
groups animals were dosed at 2 9 106 IU at 0 and 4 weeks.
For the 1:10:1 blend Ad-H1 and H3 were dosed at 2 9 106
IU, and B virus at 2 9 107 IU. Sera were harvested at
3 weeks and an anti-HA IgG ELISA was performed.
N = 6/group for all groups, except N = 5 for 1:10:1
blended group. Ad adenovirus, CI conﬁdence interval,
ELISA enzyme-linked immunosorbent assay,
GMT geometric mean titer, HA hemagglutinin, IgG
immunoglobulin, i.n. intra-nasal, p.o. peroral
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control for delivery, monovalent vectors were
also given by i.m. injection using the same dose
as p.o. As was seen in mice, both vectors elicited
some cross reactivity to the homologous
antigen and to the cross lineage antigen
(Fig. 4). As an example, the Wisconsin
HA-treated animals generated a similar
antibody response to both B/Wisconsin/1/10
and B/Brisbane/60/08 HA proteins as measured
by ELISA. The Ad-B/Bris immunized animals
had a substantial response to B/Brisbane/60/08
HA but the response to B/Wisconsin/1/10 HA
was quite varied with some animals having a
much reduced response compared to the Ad-B/
Wis vaccine. The blended B-treated animals
generated a similar antibody response to both
HA types with GMTs of 1.22 9 104 ± 3.43 9 104
and 1.22 9 104 ± 3.5 9 104, respectively (Fig. 4).
In addition to total antibody titers, HAI and
MN assays were performed to detect antibodies
that could either prevent hemagglutination
(Fig. 4b) or those that could neutralize
influenza viruses (Fig. 4c). HAI assays were
performed for all groups to both Brisbane and
Wisconsin influenza viruses. Unlike total
anti-HA antibodies, there was very little cross
HAI antibody activity as is expected from the
fact that human vaccines to either strain do not
generate cross lineage protection. The response
to B/Brisbane/60/08 trended lower for Ad-B/
Bris, i.m. 160 ± 170 and p.o. 6 ± 4 (GMT ± SD)
than the B/Wisconsin/1/10 response for the
Ad-B/Wis vaccines by the same routes of
administration (806 ± 370 i.m.; 62 ± 65 p.o.).
There was a lot of variability in the Ad-B/Bris
i.m.-treated animals to B/Brisbane/60/08 which
accounts for the extremely large error bars when
plotted GMT plus 95% CI. Three of eight
animals in the Ad-B/Bris p.o. group had titers
C40 (320, 40, and 160) compared to 6/8 with
titers C40 for the Ad-B/Wis p.o. group. Eight of
eight animals in the Ad-B/Wis p.o. group had a
49 rise in titer (i.e., titers C20) compared to 3/8
for B/Brisbane/60/08. For the blended group,
the GMT HAI for B/Wisconsin/1/10 was 21 ± 53
and for B/Brisbane/60/08 was 15 ± 10. For
B/Wisconsin/1/10, 3/8 animals had titers C40
(80, 160, and 40) and 5 out of 8 had titers (C20).
For B/Brisbane/60/08 only one animal had a
titer C40 but 4/8 animals had a titer C20,
indicating a 49 rise in titer. There was no
significant difference between the individual
and blended p.o. groups for eliciting
B/Wisconsin/1/10 HAI titers (P = 0.1 by
Mann–Whitney analysis) or the frequency at
eliciting a fourfold (49) rise in HAI titers
(P = 0.3 by Fischer’s exact test).
MN data trended in a similar fashion to HAI’s
with Ad-B/Wis eliciting a stronger response
compared to Ad-B/Bris for both i.m. and p.o.,
respectively (Fig. 4c). The anti-B/Wisconsin/1/










































Fig. 3 Cross reactivity of B/Victoria (Bris) and
B/Yamagata (Wis) HA antigens post-i.n. vaccination with
Ad-B/Bris, Ad-B/Wis or a 1:1 blend of both vectors.
BALB/c mice were vaccinated with 2 9 106 IU of
Ad-Wisconsin/1/10 HA or Ad-Brisbane/60/08 HA or a
blend of both at 2 9 106 IU for each strain. Sera were
harvested 3 weeks post-vaccination and anti-HA IgG
ELISA was performed. N = 6/group for all groups. Ad
adenovirus, CI conﬁdence interval, ELISA enzyme-linked
immunosorbent assay, GMT geometric mean titer, HA
hemagglutinin, IgG immunoglobulin, i.n. intra-nasal
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for Ad-B/Bris i.m. the anti-B/Brisbane/60/08
response was 80 ± 85 at 8 weeks post the first
vaccination. For the p.o. Ad-B/Wis group the
GMT B/Wisconsin/1/10 MN was 93 ± 106 while
for the Ad-B/Bris p.o. group the B/Brisbane/60/
08 MN was 15 ± 26. 87.5% of the p.o Ad-B/Wis
group had a B/Wisconsin/1/10 titer C40 and the
same percentage was C20. For the blended
group, 62.5% had anti-B/Wisconsin/1/10 MN
titers C40 (a 49 increase) and 87.5% had titers
C20. The Ad-B/Bris groups (monovalent and
blended) induced low levels of B/Brisbane/60/
08 MN titers, with 25 and 12.5% of the mono
and blended groups with titers C20. MN titers
for H3/Perth are not shown due to high
background in the assay.
Fig. 4 Evaluation of immunogenicity to B vaccine vectors
in ferrets. Ad vectors expressing B/Brisbane/60/08
(Ad-B/Wis) or B/Wisconsin/1/10 (Ad-B/Bris) or a 1:1
blend of each were evaluated in ferrets. For the monovalent
vectors the vaccines were tested by p.o and i.m. routes of
administration. All vectors were dosed at 1 9 109 IU/
vector/ferret at day 0 and day 28. Day 56 data for (a) total
antibody by anti-HA IgG ELISA (b) HAI or (c) data MN
are shown for both antigens. N = 8 for p.o. and naı¨ve
groups, N = 3 for Ad-B/Wis, N = 2 for Ad-B/Bris i.m.
groups. Data are plotted for GMT ? 95% CI which
accounts for the large error bars for N = 2 group. Ad
adenovirus, CI conﬁdence interval, ELISA enzyme-linked
immunosorbent assay, GMT geometric mean titer, HA
hemagglutinin, HAI hemagglutinin inhibition, i.m.
Intra-muscular, IgG immunoglobulin, LOD limit of
detection, MN microneutralization, p.o. peroral
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Endoscopic Delivery of Quadrivalent
Vaccine Blend in Ferrets and Comparison
to i.m. Delivery of an Approved
Inactivated Influenza Vaccine
Monovalent A and B, bivalent A, and
quadrivalent influenza vaccines were
administered after endoscope delivery. Each
animal was given 1 9 109 IU of each vector.
Total anti-HA antibody at 8 weeks is presented
in Fig. 5a. The percent responders are shown in
Table 1. Nearly all animals in all groups
responded to the corresponding HA of the
administered vaccine with the exception of
two animals (20%) in the Ad-B/Bris group
(Group 2) and one animal (10%) in the
quadrivalent blended group (Group 6); these
animals failed to generate anti-H1 HA IgG
responses. There was substantial cross
reactivity within the influenza A and B vaccine
groups with 60% of Ad-B/Wis-treated animals
reacting against B/Brisbane/60/08 HA and 50%
of Ad-B/Bris-treated animals reacting with
B/Wisconsin/1/10 HA. Similarly, 50% of
Fig. 5 Evaluation of immunogenicity to quadrivalent
vectors in ferrets. Ad vectors expressing B/Brisbane/60/08,
B/Wisconsin/1/10, A/H3/Perth/16/09, and A/H1/
California/04/09 were evaluated in ferrets either as mono-
valent vaccines or as a divalent A blend (A/H3 and A/H1)
or as a quadrivalent blend (B/Bris and B/Wis, A/H3 and
A/H1). All vectors were dosed at 1 9 109 IU/vector/ferret.
Sera were analyzed at day 56. (a) Total antibody by
anti-HA IgG ELISA (b) HAI or (c) MS data are shown for
the different antigen strains. Note no H3 MN data are
available due to high background in the assay. d Direct
comparison between quadrivalent oral vaccine versus TIV.
N = 10 for Ad vaccine groups. N = 4 for TIV vaccine. Ad
adenovirus, CI conﬁdence interval, ELISA enzyme-linked
immunosorbent assay, GMT geometric mean titer, HA
hemagglutinin, HAI hemagglutinin inhibition, IgG
Immunoglobulin, LOD limit of detection, MN microneu-
tralization, TIV trivalent inactivated inﬂuenza vaccine
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Ad-H3-vaccinated animals reacted against H1
HA though only 20% of Ad-H1 reacted against
H3. There was no significant difference in total
anti-HA IgG titers between the monovalent
versus quadrivalent, and the quadrivalent
versus TIV groups as tested by Mann–Whitney
analysis (P = 0.08–0.99), with the exception
that the quadrivalent was significantly better
for H3 than TIV (P = 0.02).
HAI analysis was performed for all groups.
The HAI titers were not significantly different
between quadrivalent and monovalent vaccine
groups (P = 0.22–0.96) with the exception of
the H3 monovalent versus the quadrivalent
which indicated that the monovalent induced
a higher H3 HAI response (Fig. 5b; P = 0.02 by
Mann–Whitney analysis).
MN data trended similar to HAI titers though
the percent responders and the absolute geometric
titers were in general lower (Fig. 5c) for all groups
including the TIV group which elicited no MN
titers greater than 29 the assay background of 10.
Only 20% of the quadrivalent group responded
(49abovebackground) toH1N1andB/Wisconsin/
1/10 (Table 2). This increased to 40% responders
for B/Wisconsin/1/10 if a 29 above background
criteria was used. Therewere noMN titers detected
to B/Brisbane/60/08, which is consistent with our
experience in that this HA appears to be less
immunogenic than other HAs tested.
A direct head to head comparison between TIV
and the oral quadrivalent (Oral Quad) vaccine for
HAI is shown in Fig. 5d. TIV was given as a full
human dose (45 lg) protein. GMT HAI at 8 weeks
was higher for the H3 and H1 components
compared to TIV. The TIV failed to elicit anti-H1
or H3 HAI responses despite the fact that these
animals had generated a relatively strong total HA
antibody response as measured by ELISA. The
proportion of 29HAI responders was significantly
better with the oral Quad than TIV for H1HAI and
trended higher for H3 HAI (P= 0.001, P= 0.07 by
Fisher’s exact test), and trended higher for 49HAI
responses (P= 0.07,P= 0.23byFisher’s exact test).
Table 3 has detailed these comparisons. The Ad-B/
Bris monovalent (GMT 16.25± 73.98) and the
quadrivalent vaccine (11.23± 10.59) had about
the same anti-B HAI response as TIV
(16.82± 14.14; Fig. 5b, d). TIV had a similar
number of B/Brisbane/60/08 responders
compared to the quad vector, 50 versus 40% for
49 above background (background is 5), 100
versus 40% for 29 above background (Table 2).
As there is no B/Yamagata component in TIV, the
anti-Wisconsin/1/10 HAI response cannot be
compared.
Table 1 Total antibody responders in monovalent and multivalent groups in ferrets
Group % anti-HA IgG responders
B/Wisconsin/1/10 B/Brisbane/60/08 H3/Perth/16/09 H1/California/07/09
Ad-Wis 100 60 ND ND
Ad-Bris 50 70 ND ND
Ad-Perth ND ND 100 60
Ad-CA409 ND ND 20 100
Ad-Perth/Ad-CA409 ND ND 100 100
Ad-Wis/Bris/Perth/CA409 100 100 100 90
TIV N/A 100 100 100
N/A not applicable, N/D not done, TIV trivalent inactivated inﬂuenza vaccine
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DISCUSSION
Seasonal influenza vaccines have advanced to
provide greater protection against multiple flu
strains. The original influenza vaccines were
monovalent vaccines against single influenza
subtypes [16]; however, due to co-circulation of
multiple strains and the unpredictable nature of
which strain might become the dominant strain
in an influenza season, influenza vaccines have
become more complex to account for these
risks. This evolution led to the development
and approval of quadrivalent influenza vaccines
in the last four years (Fluarix Quadrivalent,
GlaxoSmithKline Biologicals; FluLaval
Quadrivalent, ID Biomedical Corp; Fluzone
Quadrivalent, Sanofi Pasteur Inc.); and FluMist
Quadrivalent, Medimmune, LLC) [36]. This
Table 2 Total MN responders in monovalent and multivalent groups in ferrets
Group % MN responders
B/Wisconsin/1/10 B/Brisbane/60/08 H3/Perth/16/09 H1/California/07/09
Ad-Wis 40 (50) 0 0 0
Ad-Bris 0 30 (30) 0 0
Ad-Perth 0 0 N/A 0
Ad-CA409 0 0 N/A 30 (30)
Ad-Perth/Ad-CA409 ND ND N/A 60 (60)
Ad-Wis/Bris/Perth/CA409 20 (40) 0 N/A 20 (20)
TIV N/A 0 N/A 0
Percentage responders with fourfold increase in titer are shown. The percentage in () represents responders with a twofold
increase in titer
N/A not applicable, N/D not done, TIV trivalent inactivated inﬂuenza vaccine
Table 3 Total HAI responders in monovalent and multivalent groups in ferrets
Group % HAI responders
B/Wisconsin/1/10 B/Brisbane/60/08 H3/Perth/16/09 H1/California/07/09
Ad-Wis 60 (90) ND ND ND
Ad-Bris ND 40 (40) ND ND
Ad-Perth ND ND 90 (90) ND
Ad-CA409 ND ND ND 90 (100)
Ad-Perth/Ad-CA409 ND ND 60 (90) 100
Ad-Wis/Bris/Perth/CA409 50 (100) 30 (70) 50 (70) 70 (100)
TIV N/Aa 50 (100) 0 0
Percentage responders with fourfold increase in titer are shown. The percentage in () represents responders with a twofold
increase in titer
N/A not applicable, N/D not done, TIV trivalent inactivated inﬂuenza vaccine
a N/A as Fluzone does not have a vaccine component against B/Wis/1/10 or any other Yamagata strain
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development has also been fueled by
improvements in the capacity of production,
which can accommodate these additional
components. Additional improvements in
technology have led to further advances in
influenza vaccines. In 2012, the first cell
culture-derived influenza vaccine, Flucelvax
(Novartis Vaccines & Diagnostics, Inc.), rather
than egg-derived vaccine, was approved, which
can bypass potential limitations on egg
availability. A number of novel subunit
approaches based on injectable HAs have or
are in the process of being commercialized and
include the use of baculovirus-derived HA,
Flublock (Protein Sciences Corporation),
baculovirus-derived influenza vaccine-like
particles [17], or the use of bacterial expressed
flagellin-HA chimeras as injectable vaccines
[18]. Similarly, our approach is a departure
from traditional egg-derived influenza
vaccines, using cell culture-derived adenovirus
as a vector. Instead of injecting a subunit of HA,
our approach delivers a vector that co-expresses
influenza HA and a dsRNA adjuvant to improve
immune recognition of the HA [6]. We have
delivered vaccine to humans in tablet or in
liquid form, with the tablet showing slightly
better HAI responses (Liebowitz et al. [8] and
Kim et al., unpublished data). The current study
demonstrates that this platform can be used to
generate multivalent adenovirus vaccines, and
is achieved by blending multiple monovalent
vaccine vectors. This study is unique as it is the
first published study using adenoviruses as
vaccine vectors for a quadrivalent influenza
vaccine and using an oral model of delivery.
This study primarily demonstrates that a
blended quadrivalent vaccine is effective at
inducing antibody responses with minimal
interference to four influenza HA antigens
(H1, H3, B/Victoria, and B/Wisconsin) after
endoscopic delivery in ferrets. To model a
quadrivalent tablet vaccine, all four
monovalent vaccines were mixed and
delivered to the same location in the ferret
intestine by endoscope. In this study, the
quadrivalent vaccine induced 90–100%
responders by ELISA, which was comparable to
the percent responders induced for the
monovalent vectors (70–100%) and 30–70%
responders with a 49 rise in HAI for the quad
vaccines (70–100%) responders with a 29 rise.
This immunogenicity compares well to the
immunogenicity of commercial vaccines in
humans [37]. We expect the vaccine would
provide protection even in the absence of HAI
responses as we previously demonstrated that
protection against H5N1 using this platform
correlated with total antibody and not HAI [6].
The rAd doses tested in ferrets in this study were
relatively low (1–10%) compared to human
doses where we have seen substantial immune
responses in clinical trials [8, 9] and compare
well with the immune response generated to a
full human dose of TIV that we evaluated
concurrently. The HA protein made from a
gene-based vaccine, such as ours, cannot be
measured because it is made inside each subject
or animal, so the best way to compare is in
equivalent human doses.
Of interest was the fact that the TIV vaccine
at a full human dose, by the recommended
route of delivery, only induced HAI responses to
B/Brisbane, and no HAI responses to A/H1N1 or
A/H3N2. A published study by Skowronski et al.
[19] has also noted that TIV vaccines are poor
HAI inducers in influenza-naive ferrets. Pearce
et al. [20] found in ferrets that the best HAI
response in the TIV was to B/Brisbane/60/08,
(Titers 20–80) after a single immunization and
generated a low HAI response to the other
seasonal components after two immunizations.
In contrast, our vaccine induced HAI responses
to all antigens and a similar response to the
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B/Brisbane/60/08 antigen as TIV. A major
question is what accounts for the difference in
HAI observed in ferrets between our vaccine and
the tested TIV. As the ferrets used in these
studies are screened and selected for animals
that have negative HAI titers to major influenza
strains, influenza vaccine studies in ferrets are
essentially priming studies. Given that the
results obtained with 1:100 (1 9 109 IU) of a
rAd human dose (1 9 1011 IU) were equal or
better than a full TIV dose in inducing HAI
responses, it is possible that rAd makes for a
superior priming vaccine in naı¨ve individuals.
One possible explanation for the priming
difference is that a vector-based approach
elicits a superior T cell response (reviewed in
[21, 22]), and that this can improve HAI titers in
the absence of pre-exposure to the matched
influenza strain. Several investigators have
demonstrated the ability of adenovirus to
induce strong T cell responses in animals and
humans [9, 23]. Observations for the role of T
cell help in improved vaccine responses have
been made for H5 and H1 pandemic strains in
humans, where enhanced CD4 T cell responses
to HA promoted higher HAI titers [24, 25]. One
possibility is that the effector T cell help
induced at each immunization provides for
higher antibody responses at each time point
so the boost is much more effective. The other
possibility is that memory CD4 T cell responses
induced after the first immunization allows for
better HAI responses upon the second
immunization. T cell responses in ferrets are
not easy to measure, so careful measurements of
T cell responses and HAI post-immunization
will need to be performed in HAI-naı¨ve humans
to demonstrate priming potential.
The approach we have taken of co-delivering
a blend of four vaccine vectors to a specific
location in the ferret intestine proved effective
at eliciting immune responses, but the use of
rAd in a tablet format allows for alternative
approaches. For delivery to humans we could
take a similar approach to the ferret study by
blending all four strains together in a single
tablet. Alternatively, a quadrivalent vaccine
could be administered as four tablets with
each tablet delivering a vaccine for one of the
targeted quadrivalent strains. The advantage of
this single strain per tablet approach is that if
late season changes were needed on one strain,
the other three strain tablets would not be
impacted. Each strain would be individually
released and kept, and all four vaccines could be
handed out at once or given as they were made.
It would be difficult to take the same approach
with an injected vaccine because taking four
separate shots for influenza would be difficult to
sell, and if all strains were blended together, all
components would need to be discarded after a
single strain change. An additional advantage of
the rAd-based approach is that multiple
antigens could fit on one vector. This was
demonstrated for a tetravalent adenovirus
dengue vaccine generated by a combination of
blending and expressing multiple antigens on
the same adenovirus backbone, and provided
significant protection to four dengue serotypes
in rhesus monkeys [26]. We have explored a
similar approach and have expressed multiple
genes including two HA genes on single Ad
vectors using the foot and mouth 2A linker
sequence, which permits the expression of
multiple transcripts from a single ORF ([27]
and data not shown). This approach has the
advantage of reducing the production
requirements of the individual vector
components.
Pre-existing immunity to adenovirus, or to
any vector, can be problematic when using that
vector to deliver and express a vaccine antigen.
In studies by Ledgerwood et al. [28], an
adenovirus used to express an Ebola virus
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antigen was not as potent in humans with
pre-existing neutralizing antibody responses to
the adenovirus as in humans without
neutralizing antibody responses. One method
to potentially circumvent this problem is to
choose a vector with low seroprevalence in
humans such as simian adenoviruses or
engineered chimeric adenoviruses [29, 30].
There are problems with this novel vector
approach in that not all vectors are equally
immunogenic as adenovirus type 5, and once
the vaccine vector is used in a human, that
vector will not be useful for a new indication or
a boost. Injected adenoviruses elicit a very
strong anti-vector response that can block
subsequent uses or administrations. The
situation would get extremely complicated if
adenoviral vectors were in wide-scale human
use, and vaccine developers were forced to
screen people for specific antibody titers,
before deciding whether the vaccine could be
given. A different alternative is to deliver
adenoviruses orally, which appears to
circumvent neutralizing antibody responses
and selectively elicit anti-transgene immune
responses (not anti-vector antibody responses)
[6, 31]. In our human tablet study, pre-existing
immunity to adenovirus 5 had no effect on the
ability to elicit HAI responses; the subject with
the highest HAI response to the vaccine also
had the highest pre-existing anti-adenovirus
neutralizing antibody response [8].
Future human trials will likely follow a
similar path as our ferret studies, first testing A
and B monovalent vaccines and then testing
combinations to evaluate efficacy and possible
interference effects. Multivalent approaches
using either DNA or viral vectors such as Ad
are not new. A DNA vaccination approach in
mice using blends of HA expressing plasmids
against multiple H3 strains increased the breath
of protection to multiple strains compared to
monovalent vaccines alone [32]. Blends of
adenovirus vaccine vectors expressing HIV
antigens have previously been tested in
animals without signs of immunological
interference between vaccine antigens [33].
Given our success of this oral platform in
humans, plus the encouraging response
described here in ferrets, it is our intention to
evaluate such blends in future human trials.
Only through clinical trials can it be
determined whether such multivalent vaccines
will prove efficacious as vaccines.
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